3 PROGRESS DURING THE CURRENT FUNDING PERIOD 4 PROGRAM LEADERSHIP 5 PROGRAM AS AN INTEGRATED EFFORT 5 COLLABORATING INSTITUTIONS 5 PROJECT AND CORE SUMMARIES OF DISCUSSION 5 PROTECTION OF HUMAN SUBJECTS (Resume) 8 VERTEBRATE ANIMALS (Resume) 8 ADDITIONAL REVIEW CONSIDERATIONS 8 BUDGETARY OVERLAP 8 PROJECT 1: Mediators of Lung Adenocarcinoma Metastasis 9 PROJECT 2: Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers 15 PROJECT 3: Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lung Cancer 23 PROJECT 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets 31 CORE A: Molecular Profiling and Pathology 39 CORE B: Biostatistics and Bioinformatics 44 CORE C: Administration 49 COMMITTEE BUDGET RECOMMENDATIONS 53 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): Since molecular events underlie clinical events, we hypothesize that unraveling mechanisms of intracellular signaling and metastasis in lung cancers will lead to the identification of targets for therapy for these illnesses and for individul patients. Our roles in the development of EGFR and ALK kinase inhibitors and the discoveries that mutations in EGFR and KRAS genes and ALK re-arrangements underlie sensitivity and resistance to these agents have demonstrated the practicality and potential of this approach. We propose 4 research projects and 3 cores built on an iterative research process uniting clinical and laboratory observations that have linked mutations in tumors to improved outcomes in patients. This grant embraces investigators, technologies, and pathways, each focused by a specific clinical question, proposing to identify targets for therapies in lung cancers. Project 1 ill characterize mediators of metastasis in lung cancers that can serve as targets for intervention. Project 2 attacks "pan-refractory" KRAS-driven tumors by targeting ERK and its feedback inhibition of upstream signaling in KRAS- and BRAF-driven lung cancers. RP3 will investigate mechanisms and modulators of sensitivity and resistance to EGFR inhibitors, elucidating the role of HER2 and identifying the intrinsic regulatory domains of EGFR-mutant kinases required for function. Project 4 uses innovative mouse models and RNA interference to interrogate lung cancer biology and therapy, focusing on "gain of function" p53 mutations and oncogenic drivers on 8p that cooperate with EGFR and KRAS mutations. Our Molecular Profiling &Pathology Core crystallizes nearly a decade of experience in specimen collection, precise pathologic characterization in mouse and annotated human samples, mutation testing, and gene profiling in lung cancers to enrich and support each project. The Biostatistics and Bioinformatics Core ensures consistency in biostatistical analyses, unifies information exchange, and provides projects with additional analytic capabilities. The Administration Core facilitates communication and dissemination of findings and provides the forum for the PIs and the Executive and Scientific Advisory Committees to ensure rigorous scientific review and reassessment of priorities.

Public Health Relevance

Lung cancers are America's leading cancer killers, responsible for 158,000 deaths this year. This grant addresses the two most critical roadblocks to improving the care and curability of persons with these illnesses: (1) understanding how cancers spread (metastasis) and (2) the lack of highly effective medicines to prevent spread or to eradicate cancers that have spread from the lung.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA129243-06
Application #
8340075
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Program Officer
Arya, Suresh
Project Start
2007-07-23
Project End
2017-08-31
Budget Start
2012-09-12
Budget End
2013-08-31
Support Year
6
Fiscal Year
2012
Total Cost
$1,777,814
Indirect Cost
$642,477
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Yu, Helena A; Arcila, Maria E; Harlan Fleischut, Megan et al. (2014) Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol 9:554-8
Meador, Catherine B; Micheel, Christine M; Levy, Mia A et al. (2014) Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 20:2264-75
Valiente, Manuel; Obenauf, Anna C; Jin, Xin et al. (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002-16
de Bruin, Elza C; Cowell, Catherine; Warne, Patricia H et al. (2014) Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 4:606-19
Rekhtman, Natasha; Borsu, Laetitia; Reva, Boris et al. (2014) Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. J Thorac Oncol 9:e1-3
Yu, H A; Arcila, M E; Hellmann, M D et al. (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25:423-8
Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34
Yu, Helena A; Riely, Gregory J; Lovly, Christine M (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20:5898-907
Pirazzoli, Valentina; Nebhan, Caroline; Song, Xiaoling et al. (2014) Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep 7:999-1008
Haq, Rizwan; Fisher, David E; Widlund, Hans R (2014) Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 20:2257-63

Showing the most recent 10 out of 59 publications